Articles by Heidi M. Mansour - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

Keyword Location
About Search
Articles by Heidi M. Mansour

Heidi M. Mansour


Heidi M. Mansour, Ph.D., R.Ph.
Assistant Professor of Pharmaceutics & Drug Delivery, UK College of Pharmacy
Faculty Associate, UK Center of Membrane Sciences

Dr. Mansour currently holds faculty appointments and graduate appointments at the University of Kentucky (UK) College of Pharmacy, is a graduate faculty member at the University of North Carolina-Chapel Hill (UNC-Chapel Hill), and faculty associate of the UK Membrane Center. She is a faculty mentor in the UK Engineered Bioactive Interfaces and Devices Program funded through the National Science Foundation Integrative Graduate Education Research Training (NSF IGERT) Program and the NSF Research Education for Undergraduates (NSF REU) Training Program joint with the UK College of Engineering. She is also a faculty mentor in the National Cancer Institute-Cancer Nanotechnology Training Center (NCI-CNTC).

Articles
Sustained-Release Injectable Drug Delivery
November 1, 2010

A review on the current status of long-acting injectables, including commercially marketed products. This article is part of a special Drug Delivery issue.

It's Only Natural: Using Polymers in Drug Delivery
January 2, 2009

A book explains the many pharmaceutical applications of polymers from natural sources.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What impact do mega-mergers of biopharmaceutical companies have on the development of new drugs?
Improves the quality and number of innovative drugs available to patients.
Restricts innovation and the development of new drugs.
Has no impact on drug development.
Do not know.
Improves the quality and number of innovative drugs available to patients.
29%
Restricts innovation and the development of new drugs.
54%
Has no impact on drug development.
4%
Do not know.
13%
Eric Langer Outsourcing Outlook Eric LangerOutsourcing No Longer Just for Cost-Cutting
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerSeeking Alternative Catalyst Solutions
Jill Wechsler Regulatory Watch Jill Wechsler Global Expansion Shapes Drug Oversight
Chris Burgess Statistical Solutions Chris BurgessIs a Sample Size of n=6 a Magic Number?
Sean Milmo European Regulatory WatchSean MilmoRegulating the Environmental Impact of Pharmaceuticals
FindPharma Custom Search
Click here